Wasatch International Growth Fund Comments on Medy-Tox

Author's Avatar
May 29, 2015

Medy-Tox, Inc. (XKRX:086900) has developed the next generation of Botox and has a strong supply partner in Allergan§§ to distribute it globally. Medy-Tox’s new product, Innotox, has a number of benefits over Botox such as greater stability, no animal by-products, and greater precision when mixing the final solution. The market applications for Innotox and Botox are increasing, both for cosmetic purposes and for therapeutic uses. The founder of Medy-Tox is a scientist and continues to drive new-product innovation at the company.

From Wasatch International Growth (Trades, Portfolio) Fund’s Q1 2015 Commentary.